论文部分内容阅读
目的:探讨布地奈德混悬液联合特布他林雾化吸入治疗急性加重期慢性阻塞性肺疾病(AECOPD)患者的临床疗效。方法:对2012年9月至2014年2月在我院呼吸内科住院的31例AECOPD患者的临床资料进行回顾性分析。31例患者在常规治疗基础上,配合布地奈德混悬液及特布他林雾化吸入治疗,布地奈德混悬液2 m L、特布他林雾化溶液2 m L、雾化吸入,2次/天,7天为1个疗程。观察患者的临床疗效、肺功能(PEF、FEV1)及药物不良反应等。结果:治疗1个疗程后,31例患者总有效率为93.4%,治疗期间均无明显的不良反应。结论:布地奈德混悬液联合盐酸特布他林雾化吸入治疗COPD急性加重期,能显著改善患者肺功能,疗效肯定,无明显不良反应,值得临床推广应用。
Objective: To investigate the clinical efficacy of budesonide suspension combined with terbutaline nebulization in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: The clinical data of 31 AECOPD patients hospitalized in our department of respiratory medicine between September 2012 and February 2014 were analyzed retrospectively. On the basis of routine treatment, 31 patients were treated with budesonide suspension and terbutaline inhalation, 2 m L of budesonide suspension and 2 m L of terbutaline injection solution, , 2 times / day, 7 days for a course of treatment. To observe the clinical efficacy, pulmonary function (PEF, FEV1) and adverse drug reactions. Results: After a course of treatment, the total effective rate of 31 patients was 93.4%. There was no obvious adverse reaction during the treatment. Conclusion: Budesonide suspension combined with inhalation of terbutaline HCl can effectively improve pulmonary function in patients with acute exacerbation of COPD. The curative effect is affirmative and there is no obvious adverse reactions, which is worthy of clinical application.